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Use of autologous bone marrow mononuclear cell
implantation therapy as a limb salvage procedure
in patients with severe peripheral arterial disease
Randall W. Franz, MD, FACS, RVT,a Alan Parks, DO,b Kaushal J. Shah, MD, RPVI,a Thomas Hankins, CCP,c
Jodi F. Hartman,MS,d andMichelle L.Wright,MPH,d Columbus and Gahanna, Ohio
Background: Few options other than amputation exist for some patients with peripheral arterial occlusive disease (PAD)
and severe anatomical limitations.
Methods: This prospective study presents short-term results of dual intramuscular and intra-arterial autologous bone
marrow mononuclear cell (BM-MNC) implantation for the treatment of patients with severe PAD in whom amputation
was considered the only viable treatment option. Baseline, two-week, and three-month evaluations were conducted.
Ankle brachial indices (ABI) were calculated for both the dorsal pedis and the posterior tibial arteries. Rest pain and ulcer
healing also were assessed. Success was defined as meeting the following four criteria: improvement in ABImeasurements;
relief of rest pain; ulcer healing, if applicable; and absence of major limb amputations. Patients not undergoingmajor limb
amputations continued to be monitored for subsequent procedures.
Results:Nine patients for whom limb amputationwas recommended underwent this procedure. The study populationwas
comprised of five females and four males, with a mean age of 61.7 years. Eight (88.9%) patients had rest pain. Seven
(77.8%) patients also had diabetes. Non-healing ulcers were present in eight (88.9%) cases. After the procedure,
non-significant improvements of 0.12 and 0.08 in ABI were observed for the dorsalis pedis and posterior tibial ankle
arteries, respectively. Three (33.3%) major amputations subsequently were performed, including a below-knee amputa-
tion 4.1 weeks after the BM-MNC implantation and two above-knee amputations at 5.4 and 11.0 weeks after the
procedure. The six (66.7%) patients who did not have major amputations demonstrated improvement in symptom
severity three months after the procedure, as evidenced by alleviation of rest pain and improvements by at least one level
in Rutherford and Fontaine classifications, and have not required amputations at a mean follow-up of 7.8 months.
Complete wound healing was achieved within three months in all patients who had ulcers prior to BM-MNC
implantation and for whom amputation was not required. This specific BM-MNC implantation technique was fully
successful in three (33.3%) patients, as major amputation was avoided and the other applicable criteria were met. Five
(55.6%) additional patients demonstrated success in at least one of the four criteria.
Conclusions: With eight (88.9%) of nine patients showing some level of improvement and amputation avoided in six
(66.7%) patients, these short-term results indicate the use of BM-MNC implantation as a means of limb salvage therapy
for patients with severe PAD shows promise in postponing or avoiding amputation in a patient population currently
presented with few alternatives to amputation. (J Vasc Surg 2009;50:1378-90.)The prevalence of peripheral arterial occlusive disease
(PAD) has been increasing in recent years, affecting a
reported eight to 12 million people in the United States.1,2
Risk factors associated with the development of PAD in-
clude individuals aged 65 years and older, nicotine use,
diabetes mellitus, hypertension, hypercholesterolemia, and
family history of cardiovascular disease.1,3,4 Although pa-
tients with PAD may be asymptomatic, intermittent clau-
dication (leg pain after walking) is the most common
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1378presenting symptom.2-4 As PAD progresses, leg pain at rest
and/or ischemic ulceration often are hallmark signs of
ischemia.5,6
Treatment for PAD is dependent on the severity of the
symptoms and typically ranges from conservative pharma-
ceutical management with risk factor modifications to en-
dovascular or open surgical interventions in more severe
cases.2,6 Patients with end-stage PAD often have multi-
level disease or are unable to be treated with these tradi-
tional methods, leaving major limb amputation as the only
treatment option.2,6 Over 100,000 limb amputations are
performed each year due to PAD.5 Furthermore, the an-
nual cost associated with amputations in the United States
is an estimated $13 billion.7,8
In the past 10 years, therapeutic angiogenesis using
bone marrowmononuclear cells (BM-MNC) has become a
promising treatment for patients with moderate to severe
PAD who have no other treatment options.6,9 The goal of
treatment is to promote neoangiogenesis (new vessel for-
mation) in ischemic tissues.10 Bone marrow cells possess
various types of primitive cells that are able to differentiate
Fir
, non-
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growth factors that promote neoangiogenesis and endo-
thelialization.10-14 Previously published animal and clinical
Table I. Demographics, limb involvement, and ischemia s
Patient
number
Age
(years) Gender
Smoking
status
Presence of
Non-healing ulcers
(Y or N)
1 58 Male Smoker Y
2 73 Female Smoker N
3 85 Male Non-smoker Y
4 43 Female Smoker Y
5 75 Female Smoker Y
6 54 Female Smoker Y
7 57 Female Smoker Y
8 60 Male Smoker Y
9 55 Male Smoker Y
Table II. Co-morbidities and prior vascular procedures lis
Patient
number
Cerebrovascular
accident
Chronic
obstructive
pulmonary
disease
Coronary
artery
disease Diabetes Hyp
1 Absent Absent Absent Present
2 Present Absent Present Absent
3 Absent Absent Absent Present
4 Present Absent Present Present
5 Absent Present Absent Absent
6 Absent Absent Absent Present
7 Present Present Present Present
8 Present Present Present Present
9 Absent Absent Absent Present
ESRD, End-stage renal disease; HIT, heparin-induced thrombocytopenia.
Table III. Dorsalis pedis artery and posterior tibial artery
before and after BM-MNC implantation and current ampu
Patient
number
Ankle brachial index (ABI)
Dorsalis pedis artery Posterior tibial artery
Pre Post
Change
(Post–Pre) Pre Post
Change
(Post–Pre)
1 0.00 0.00 0.00 0.00 0.00 0.00
2 0.45 0.47 0.02 0.40 0.46 0.06
3 0.50 0.53 0.03 0.48 0.65 0.17
4 0.43 0.39 0.04 0.47 0.44 0.03
5 0.29 0.44 0.15 0.28 0.35 0.07
6 0.00 0.00 0.00 0.00 0.22 0.22
7 0.00 0.16 0.16 0.00 0.00 0.00
8 0.00 0.74 0.74 0.47 0.69 0.22
9 NC NC — NC NC —
ABI, Ankle brachial index; BM-MNC, bone marrow mononuclear cell; NCstudies have demonstrated that implantation of autologousBM-MNC is a safe and effective technique in the develop-
ment of collateral arteries.2,6,9-12,14-22 In this study, dual
intramuscular and intra-arterial autologous BM-MNC im-
listed by patient
er status
Rutherford
classification
Fontaine
classification
If Y, ulcer
location
Presence of
gangrene
(Y or N) Grade Category
st toe Y III 6 IV
— N II 4 III
ot Y III 5 IV
terior tibia N III 5 III
st, second, and
fourth toes
Y III 6 IV
wer extremity
and foot
N III 5 IV
ot N III 5 IV
ot Y III 5 IV
st toe N III 5 IV
y patient
idemia Hypertension Other
Prior vascular procedure
Major open Endovascular
nt Present — Yes Yes
nt Present — Yes No
nt Present — No Yes
nt Present Seizure Yes Yes
nt Present — No Yes
nt Present Hypothyroid Yes Yes
nt Present — Yes Yes
nt Present ESRD, HIT Yes No
nt Present ESRD No No
measurements, rest pain, and ischemic ulceration status
n status listed by patient
est pain
Ischemic
ulceration
Major
amputation
Post-BM-MNC
(Y or N)
If yes, type
of major
amputatione Post Pre Post
ent — Present — Y Above knee
ent Absent Absent — N —
ent Absent Present Present N —
ent Absent Present Absent N —
ent — Present — Y Below knee
ent — Present — Y Above knee
— Present Absent N —
ent Absent Present Absent N —
ent Absent Present Present N —
compressible.tatus
Ulc
Fir
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Fir
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Foted b
erlip
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Prese
Prese
Prese
AbseABI
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Pres
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Presplantation was performed in patients with severe PAD in
stand
JOURNAL OF VASCULAR SURGERY
December 20091380 Franz et alwhom amputation was considered as the only viable treat-
ment option with the goal of improving tissue perfusion to
salvage the limb. The authors hypothesized that patients
undergoing autologous BM-MNC implantation would ex-
perience improved ankle-brachial index (ABI) measure-
ments, relief of rest pain, and ulcer healing, when applica-
ble, compared with pre-procedure evaluation and would
not require major limb amputation.
METHODS
This prospective study was initiated with institutional
review board approval and was designed to evaluate the
outcomes of autologous BM-MNC implantation for the
treatment of severe PAD. All procedures were performed
by one of the senior authors using standardized interven-
tional techniques. Between December 2007 and January
2009, nine patients provided written informed consent and
were enrolled in the study. Patients at least 18 years of age
were eligible for study participation if they had severe
limb-threatening PAD, defined as ABI less than 0.4 or
presence of non-healing ischemic ulcers; and stenosis or
occlusion of two of the following lower extremity arteries:
anterior tibial, posterior tibial, and peroneal. Additional
stenosis or occlusion may be present proximally to these
vessels. Major amputation was recommended for these pa-
tients due to limb-threatening ischemia or the presence of
ulcers that could not be healed by conservative wound
management. Patients with conditions that precluded rec-
ommendation of traditional endovascular or open bypass
treatments were eligible for inclusion. Patients younger
than 18 years of age and those eligible to undergo tradi-
tional endovascular or open bypass for the treatment of
PAD were excluded from study participation. Pregnant
women, prisoners, patients with mental retardation, and
those unable to consent for participation independently
also were excluded. At the time of enrollment, all patients
were receiving maximum medical therapy for PAD at the
discretion of the managing vascular surgeon and wound
care management, when applicable.
Study design. Patients with ulcers received extensive
wound care management per routine protocols at the wound
care clinic associated with our institution prior to and after
BM-MNC implantation. Evaluations were conducted prior
to BM-MNC implantation and at two weeks and three
Table IV. Comparison of dorsalis pedis artery and posteri
implantation
Dorsalis pedis artery ABI
Pre-implantation
n  8
Post-im
n
Mean  SD 0.21  0.23 0.34
Median 0.15
Range (min-max) 0.00-0.50 0.0
ABI, Ankle brachial index; BM-MNC, bone marrow mononuclear cell; SD,months after the procedure. The extent of acute ischemiafor the involved limb was classified using the Rutherford
criteria, whereas the Fontaine classification was used
to classify PAD.23,24 The two-week post-procedure as-
sessment was conducted to determine the presence of
procedure-related complications only and no study data
were collected. Rest pain and ulcer status, if applicable,
were assessed at the pre-treatment and three-month
post-treatment evaluations.
Routine angiography was performed prior to the bone
marrow harvest to identify the specific location of stenosis
or occlusion. When possible, Doppler-guided arterial seg-
mental pressures of the dorsal pedis artery and posterior
tibial artery weremeasured prior to the procedure and three
months after BM-MNC implantation. Ankle brachial indi-
ces were calculated separately for each of the lower extrem-
ity arteries by dividing the ankle systolic pressure of the
individual artery by the brachial artery systolic pressure.
Finally, amputations also were monitored and categorized
into minor and major limb amputations. Individual toe
and transmetatarsal (TMT) amputations were consid-
ial artery ABI measurements before and after BM-MNC
Posterior tibial artery ABI
tation Pre-implantation
n  8
Post-implantation
n  8
.26 0.26  0.23 0.31  0.27
0.34 0.40
4 0.00-0.48 0.00-0.69
ard deviation.
Table V. Outcomes of BM-MNC implantation using
four-pronged definition of success
N  9
Improvement in all four criteria for ulcer patients, or
in all three applicable criteria for non-ulcer
patients
3 (33.3%)
● Improvement in ABI measurement(s), absence
of rest pain, ulcer healing, and no major limb
amputations
1 (11.1%)
● Improvement in ABI measurement(s), absence
of rest pain, and no major limb amputations
1 (11.1%)
● Improvement in ABI measurement(s), ulcer
healing, and no major limb amputations
1 (11.1%)
Improvement in three of the four criteria 2 (22.2%)
● Improvement in ABI measurement(s), absence
of rest pain, and no major amputations
1 (11.1%)
● Absence of rest pain, ulcer healing, and no
major amputations
1 (11.1%)
Improvement in at least two of the four criteria 1 (11.1%)
● Absence of rest pain and no major amputations 1 (11.1%)
Improvement in at least one of the four criteria 2 (22.2%)
● Improvement in ABI measurement(s) 2 (22.2%)
No improvement in any criteria 1 (11.1%)
ABI, Ankle brachial index; BM-MNC, bone marrow mononuclear cell.or tib
plan
 8
 0
0.42
0-0.7ered minor, whereas below- and above-knee amputa-
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undergoing major limb amputations continued to be
monitored for subsequent procedures. Success of autol-
ogous BM-MNC implantation was defined as meeting
the following four criteria: improvement of ABI mea-
surements; relief of rest pain; ulcer healing, if applicable;
and absence of major limb amputations.
Statistical analysis. Statistical analysis was performed
using SigmaStat Software, version 2.0 (SPSS, Inc, Chicago,
Ill). Descriptive statistics, including mean, median, stan-
dard deviation, frequency, and percentage were used to
describe demographic and clinical data. Ankle brachial in-
dex measurements were compared between the pre- and
post-procedure time intervals, as possible. Paired t test was
performed to compare normally distributed continuous
variables, whereas the Wilcoxon signed rank test was em-
ployed to compare non-normally distributed variables.
Ninety-five percent confidence intervals were used through-
out the statistical analysis. Statistical differences were consid-
ered significant when the P-value was less than or equal to
0.05 with a power of at least 0.8.
Bone marrow harvest and isolation of mononuclear
cells. While patients were under minimum alveolar con-
centration (MAC) and local anesthesia, autologous bone
marrow aspirate was obtained from the anterior superior
iliac spine (ASIS), which was prepped and draped prior to
surgery. A #11 blade was utilized to create a 2-mm incision
anterior to the ASIS. A three-hole bone marrow needle
(DePuy, Inc., Warsaw, Indiana, USA) with a syringe con-
taining anticoagulant (heparin, 1,000 units/mL) was uti-
lized for the bone marrow aspiration. For a patient with
heparin-induced thrombocytopenia, only saline was used in
the syringe. The initial trajectory of the needle was medially
in line with the pelvic wing and aimed slightly posterior to
the iliac tubercle to allow entry into the medullary canal
directly beneath it. The needle tip was advanced through
the cortex by gently tapping the needle with a mallet. A
total of 50 mL to 60 mL of aspirate was obtained. The
aspirate was placed in a centrifuge and was spun at 2400
rpm for twelve minutes to concentrate the bone marrow cells
(GenesisCS Component Concentrating System; EmCyte
Corporation, Fort Myers, Fla).
Autologous BM-MNC implantation. The concen-
trated cells obtained after centrifugation were placed in a
sterile container. The cells were immediately reinjected
intramuscularly and intravascularly into the patient using
injection sites determined by location of stenosis and/or
occlusion on angiogram obtained prior to implantation.
For the intramuscular injections, 2 mL of aspirate were
injected intramuscularly into six different lower leg sites in
a standardized fashion to approximate the disease surface
area. Intramuscular injections specific to the calf started 8
cm above the medial and lateral malleolus in the midline of
the calf and continued proximally in 8-cm increments.
Intramuscular injections in the thigh began 8 cm above the
knee joint, bothmedially and laterally, and continued prox-
imally in 8-cm increments. For the intra-arterial injection,
12 mL of aspirate was injected intravascularly in a 4 Frenchcatheter in 2 mL increments, with flushing between injec-
tions. Occlusion location determined artery selection, with
injections occurring in the popliteal artery for tibial occlu-
sions and in the common femoral artery for superficial
femoral artery occlusions.
Study population. Patient demographics, ulcer sta-
tus, and the Rutherford and Fontaine Classifications are
presented in Table I. The population was comprised of five
(55.3%) females and four (44.4%) males and included six
(66.7%) African-American and three (33.3%) white pa-
tients. Themean age of the study population was 61.7 years
(SD 13.4; median 58.0; range, 43.0-85.0 years). Eight
(88.9%) patients were smokers. Six (66.7%) cases involved
the left and three (33.3%) cases involved the right lower
extremity. Aside from one patient for whom rest pain could
not be assessed due to hemiparesis from a previous cerebro-
vascular accident (CVA), all had rest pain prior to BM-
MNC implantation. The remaining patient had a non-
healing foot ulcer, but rest pain could not be assessed due
to hemiparesis occurring after a CVA prior to study enroll-
ment. Non-healing ulcers were present in eight (88.9%)
cases; six (75.0%) were on the foot and two (25.0%) were
lower extremity ulcers. Gangrene was present in four
(50.0%) of the eight cases with ulcers. Baseline Rutherford
classifications included one (11.1%) II4 (ischemic rest pain);
six (66.7%) III5 (minor tissue loss – nonhealing ulcer, focal
gangrene with diffuse pedal ischemia); and two (22.2%)
III6 (major tissue loss, extending above transmetatarsal
level, functional foot no longer salvageable). Two (22.2%)
patients had Fontaine class III PAD, corresponding to rest
pain, and seven (77.8%) patients had Fontaine class IV
PAD, corresponding to pedal necrosis.
Co-morbidities and prior vascular procedures are listed
on a per-patient basis in Table II. The co-morbidity distri-
bution for the study population was as follows: nine (100.0%)
hypertension; seven (77.8%) diabetes; five (55.6%) hyperlip-
idemia; four (44.4%) CVAs; four (44.4%) coronary artery
disease; three (33.3%) chronic obstructive pulmonary dis-
ease; two (22.2%) renal disease; one (11.1%) heparin-
induced thrombocytopenia; one (11.1%) hypothyroidism;
and one (11.1%) seizure history. Five (55.6%) patients had
previous endovascular procedures. Five (55.6%) patients
had prior major open procedures, which included bypasses
and minor amputations.
RESULTS
No procedure-related complications were reported
during the technique or at the two-week and three-month
follow-up evaluations. Table III summarizes ABI measure-
ments, rest pain, and ischemic ulceration status obtained
before and after BM-MNC implantation and also lists the
current amputation status for the nine study patients. The
ABI measurements obtained after BM-MNC implantation
are compared with the pre-implantation measurements in
Table IV. Although improvement in ABI measurements
was observed after BM-MNC implantation for both the
dorsalis pedis (mean  0.13, SD  0.26, median  0.03,
range0.4-0.74) and the posterior tibial (mean 0.09,
ll; CL
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the differences compared with the pre-implantation mea-
surements were not statistically significant.
After BM-MNC implantation, two (22.2%) patients
Table VI. Comparison of study type, procedure indicatio
studies utilizing BM-MNC for the treatment of lower extr
Study type
Intra-arterial and intramuscular BM-MNC implantation
Current Study 2009 Prospective, case series
Van Tongeren et al, J Cardiovasc
Surg 200832
Prospective, non-randomize
Bartsch et al, Clin Res Cardiol
200715
Prospective, open label,
controlled
Intra-arterial BM-MNC Implantation
Chochola et al, Int Angiol
200826
Prospective, case series
Cobellis et al, Bone Marrow
Transplant 20085
Prospective, non-randomize
controlled
Gu et al, Chin Med J 200833 Prospective, randomized
Napoli et al, Eur J Cardio Prev
Rehab 20086
Prospective, non-randomize
controlled
Intramuscular BM-MNC Implantation
Gu et al, Chin Med J 200833 Prospective, randomized
Matoba et al, Am Heart J
200821
Multi-institutional follow-up
study to Tateishi et al 200
Motukuru et al, J Vasc Surg
200831
Prospective, case series
Van Tongeren et al, J Cardiovasc
Surg 200832
Prospective, non-randomize
Wester et al, Scand J Surg
200822
Prospective, case series
De Vriese et al, J Int Med
200727
Prospective, case series
Hernandez et al, Atherosclerosis
200729
Prospective, pilot
Kajiguchi et al, Circ J 20079 Prospective, case series
Saito et al, Circ J 200736 Prospective, case series
Miyamoto et al, Circulation
200630
Prospective, case series, pilot
Nizankowski et al, Kardiol Pol
200534
Prospective, case series
Higashi et al, Circulation 200412 Prospective, case series
Saigawa et al, Circ J 200435 Prospective, case series
Esato et al, Cell Transplant
200211
Prospective, case series
Tateishi et al, Lancet 200214 Pilot, controlled
Tateishi et al, Lancet 200214 Prospective, randomized,
controlled
Intramuscular and intermetatarsal BM-MNC implantation
Durdu et al, J Vasc Surg 200628 Prospective consecutive serie
ASO, Atherosclerosis obliterans; BM-MNC, bone marrow mononuclear ce
thromboangiitis obliterans or Buerger’s disease.required minor amputations and three (33.3%) patientsrequired major amputations of the involved limb due to
continuing osteomyelitis or worsening gangrene. In two of
the five cases, improvements in ABI measurements were
observed after BM-MNC implantation. All amputation
d patient demographics between previously published
ischemia
Country Indication(s)
USA Severe PAD (Amputation recommended)
(Rutherford II or III; Fontaine III or IV)
Netherlands PAD (no options for revascularization)
(CLI or claudication)
Germany Long-Lasting Severe PAD (Fontaine IIB)
(including 3 TAO)
Czech Republic CLI (Fontaine III or IV)
Italy Severe PAD (Leriche-Fontaine III or IV)
China CLI (including 1 TAO)
Italy Advanced PAD (Fontaine III or IV)
China CLI (including 1 TAO)
Japan PAD (Fontaine II or IV) and TAO
India TAO
Netherlands PAD (no options for revascularization)
(CLI or claudication)
Norway CLI (Rutherford II or III)
Belgium ASO (Rutherford Cat 4-6)
Cuba Severe PAD/CLI
Japan ASO and TAO
Japan TAO (Fontaine III or IV)
Japan TAO
Poland ASO and TAO
Japan PAD
Japan ASO (Fontaine IIB-IV)
Japan ASO and TAO
Japan CLI
Japan CLI
Turkey TAO (Rutherford II or III)
I, chronic or critical limb ischemia; PAD, peripheral arterial disease; TAO,ns, an
emity
d
d
d
2
d
ssites healed. The two minor amputations both were trans-
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tions than would have been performed had the patients not
undergone BM-MNC implantation. The three major am-
Table VI. Continued.
BM-MNC treated patients
9 (9 limbs)
12 (12 limbs) (8 CLI; 3 claudication; 1 NA)
13 (13 limbs)
24 (28 limbs)
10 (10 limbs)
16 (17 limbs)
18 (18 limbs)
16 (18 limbs)
115 (115 limbs) (74 PAD; 41 TAO)
38 enrolled (38 limbs) (36 treated)
15 (15 limbs) (11 CLI; 3 claudication; 1 NA)
8 (8 limbs) 3 Rutherford II (all Cat 4); 5
Rutherford III (4 Cat 5; 1 Cat 6)
16 (16 limbs)
12 (12 limbs)
7 (7 limbs) (4 ASO cases; 3 TAO)
9 (9 limbs)
7 (9 limbs)
10 (10 limbs) (3 ASO; 7 TAO)
7 (7 limbs)
8 (8 limbs)
8 (8 limbs) (4 ASO; 4 TAO)
29 enrolled (29 limbs) (25 treated)
23 enrolled (23 limbs) (22 treated, 20 in analysis)
28 (28 limbs)putations were performed between 4.1 to 11.0 weeks afterBM-MNC implantation. Prior to the procedure, these
three patients had Rutherford Grade IV (1 Category 5; 2
Category 6) and Fontaine IV classifications. One (11.1%)
Gender Mean age (years)
(55.3%) females
(44.4%) males
61.7 (r, 43.0-85.0)
(25.0%) females
(75.0%) males
66.9
(23.1%) females
(76.9%) males
69.0
(45.8%) females
(54.2%) males
68.0 (median) (r, 26.0-85.0)
(40.0%) females
(60.0%) males
60.3 (r, 38.0-77.0)
(37.5%) females
(62.5%) males
(entire group)
69.5 (r, 51.0-82.0)
(entire group)
(38.9%) females
(61.1%) males
71.6 (r, 43.0-90.0)
(37.5%) females
(62.5%) males
(entire group)
69.5 (r, 51.0-82.0)
(entire group)
(21.7%) females
(78.3%) males
67 (r, 37-82) PAD Group
49 (r, 29-72) TAO Group
(0.0%) females
(100.0%) males
34.0
(33.3%) females
(66.7%) males
69.8
(50.0%) females
(50.0%) males
71.1 (r, 43.0-81.0)
(50.0%) females
(50.0%) males
78.0
(33.3%) females
(66.7%) males
62.7
(28.6%) females
(71.4%) males
53.4 (r, 37.0-67.0)
(11.1%) female
(88.9%) males
43.7 (r, 29.0-55.0)
(14.3%) female
(85.7%) males
47.9 (r, 28.0-63.0)
(40.0%) females
(60.0%) males
48.7 (r, 37.0-77.0)
(14.3%) female
(85.7%) males
64.0 (r, 51.0-74.0)
(12.5%) female
(87.5%) males
62.4 (r, 48.0-79.0)
NA 70.4 (r, 55.0-78.0)
(20.0%) females
(80.0%) males
66.0
(10.0%) females
(90.0%) males
analysis group)
69.0 (analysis group)
(10.7%) females
(89.3%) males
42.6 (r, 25.0-56.0)5
4
3
9
3
10
11
13
4
6
12
20
7
11
12
20
25
90
0
38
5
10
4
4
8
8
4
8
2
5
1
8
1
6
4
6
1
6
1
7
5
20
2
18
(
3
25patient required a below-knee amputation (BKA), whereas
ce of
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tations (AKAs). One patient requiring an AKA had a non-
viable limb and was facing a probable hip disarticulation, as
evidenced by the absence of anatomically named blood
vessels to the thigh on angiogram, with only collaterals
from the right internal iliac artery. Stem cell therapy was
performed in an effort to re-establish circulation, which
would possibly enable performing an AKA rather than a hip
disarticulation. No improvement was observed between the
ABI measurements before and after BM-MNC implanta-
tion, as ankle measurements were undetectable at both
evaluations. However, the thigh was warm on physical
examination, indicating possible improved collateral circu-
lation. Because the muscle was viable at the time of surgery,
an AKA was performed.
Major amputation was avoided in six (66.7%) of the
nine patients undergoing BM-MNC implantation. Five of
these six patients did not have rest pain at the three-month
follow-up evaluation, while rest pain could not be assessed
Table VII. Comparison of co-morbidities and ulceration
BM-MNC for the treatment of lower extremity ischemia
Smoking/n
use (
Intra-arterial and intramuscular BM-MNC implantation
Current study 2009 88.9
Van Tongeren et al, J Cardiovasc Surg 200832 83.3% (10 o
Bartsch T et al, Clin Res Cardiol 200715 38.5% (5 of
Intra-arterial BM-MNC implantation
Chochola et al, Int Angiol 200826 33.3% (8 of
Cobellis et al, Bone Marrow Transplant 20085 50.0% (5 of
Gu et al, Chin Med J 200833 NA
Napoli et al, Eur J Cardio Prev Rehab 20086 66.7% (12 o
Intramuscular BM-MNC implantation
Gu et al, Chin Med J 200833 NA
Matoba et al, Am Heart J 200821 72.2% (83 o
Motukuru et al, J Vasc Surg 200831 100.0
Van Tongeren et al, J Cardiovasc Surg 200832 86.7% (13 o
Wester et al, Scand J Surg 200822 NA
De Vriese et al, J Int Med 200727 31.0
Hernandez et al, Atherosclerosis 200729 58.3% (7 of
Kajiguchi et al, Circ J 20079 57.1% (4 of
Saito et al, Circ J 200736 NA
Miyamoto et al, Circulation 200630 85.7% (6 of
Nizankowski et al, Kardiol Pol 200534 NA
Higashi et al, Circulation 200412 100.0
Saigawa et al, Circ J 200435 NA
Esato et al, Cell Transplant 200211 NA
Tateishi et al, Lancet 200214 NA
Tateishi et al, Lancet 200214 NA
Intramuscular and intermetatarsal BM-MNC implantation
Durdu et al, J Vasc Surg 200628 100.0
ABI, Ankle brachial index; BM-MNC, bone marrow mononuclear cell.
*Instead of reporting prevalence of diabetes, Saito Y et al reported prevalenin the aforementioned patient with hemiparesis. All sixpatients exhibited as a Fontaine classification of II, which
was an improvement by at least one level from the pre-
procedure evaluation. Five (83.3%) of six patients had
Rutherford classifications of I3 (severe claudication), cor-
responding to an improvement by at least one grade com-
pared with baseline assessments. In addition, complete
wound healing was achieved within three months in these
three patients who had ulcers prior to BM-MNC implan-
tation and for whom amputation was not required, includ-
ing in one patient who had a gangrenous foot ulcer. Two of
these patients had foot ulcers; the other patient had an ulcer
on the anterior tibia. At a mean follow-up of 7.8 months
(median  7.1; SD  5.9; range, 0.50-16.8 months), no
amputations have been required for these six patients.
Outcomes also were assessed using the four-pronged
definition of success (Table V). According to this defini-
tion, BM-MNC implantation was successful in three
(33.3%) patients, as major amputation was avoided and the
other applicable criteria were met. Two (22.2%) additional
s between previously published studies utilizing
ne
Diabetes (%) Hypertension (%)
77.8% 100.0%
ts) 25.0% (3 of 12 pts) 41.7% (5 of 12 pts)
s) 38.5% (5 of 13 pts) 100.0%
s) 62.5% (15 of 24 pts) 75.0% (18 of 24 pts)
s) 70.0% (7 of 10 pts) 70.0% (7 of 10 pts)
90.6% (29 of 32 pts)
(entire group)
NA
ts) 50.0% (9 of 18 pts) 61.1% (11 of 18 pts)
90.6% (29 of 32 pts)
(entire group)
NA
pts) 47.8% (55 of 115 pts) 57.4% (66 of 115 pts)
0.0% NA
ts) 33.3% (5 of 15 pts) 46.7% (7 of 15 pts)
0.0% 50.0% (4 of 8 pts)
44.0% 88.0%
s) 75.0% (9 of 12 pts) 66.7% (8 of 12 pts)
14.3% (1 of 7 pts) 14.3% (1 of 7 pts)
22.2%* (2 of 9 pts) 11.1% (1 of 9 pts)
14.3% (1 of 7 pts) 42.9% (3 of 7 pts)
0.0% 30.0% (3 of 10 pts)
0.0% 42.9% (3 of 7 pts)
75.0% (6 of 8 pts) 100.0% (8 of 8 pts)
NA NA
72.0% (18 of 25 pts) 72.0% (18 of 25 pts)
65.0% (13 of 20 pts)
(analysis group)
70.0% (14 of 20 pts)
(analysis group)
0.0% 10.7% (3 of 28 pts)
impaired glucose tolerance.statu
icoti
%)
%
f 12 p
13 pt
24 pt
10 pt
f 18 p
f 115
%
f 15 p
%
12 pt
7 pts)
7 pts)
%
%patients met three of the four criteria for success, including
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Volume 50, Number 6 Franz et al 1385not undergoing a major amputation. One (11.1%) patient
did not require a major amputation and no longer had rest
pain. The final (11.1%) patient did not meet any of the four
criteria for success. This patient was the aforementioned
50-year-old male for whom BM-MNC implantation was
performed to avoid a probable hip disarticulation.
DISCUSSION
Treatment options for patients with severe PAD for
whom conservative management has failed and who are not
candidates for surgical interventions, such as endovascular or
open procedures, are sparse. Such patients typically must
resort to limb amputation as a final option. Beginning in
2000, several animal model studies reported successful out-
comes using stem cell therapy to improve peripheral blood
circulation.10,13,17,19,20,25 These studies subsequently
spurred early clinical trials in Asia and Europe involving
injection of mononuclear bone marrow stem cells to treat
severe PAD.3,5,6,9,11,12,14,15,21,22,26-32 Results from these
Table VII. Continued.
Hypercholesterolemia/
hyperlipidemia (%)
Non-healing
ulcers (%)
55.6% 88.9% (8 of 9 pts)
33.3% (4 of 12 pts) NA
100.0% NA
54.2% (13 of 24 pts) 58.3% (14 of 24 pts)
NA NA
NA NA
NA 44.4% (8 of 18 pts)
NA NA
16.5% (19 of 115 pts) NA
NA 100.0%
26.7% (4 of 15 pts) NA
NA 62.5% (5 of 8 pts)
69.0% 76.0%
38.0% w/ gangrene
38.0% w/o gangrene
NA 41.7% (5 of 12 pts)
28.6% (2 of 7 pts) 42.9% (3 of 7 pts)
22.2% (2 of 9 pts) 88.9% (8 of 9 pts)
14.3% (1 of 7 pts) 100.0%
NA 60.0% (6 of 10 pts)
57.1% (4 of 7 pts) 100.0%
62.5% (5 of 8 pts) NA
NA 37.5% (3 of 8 pts)
32.0% (8 of 25 pts) 24.0% (6 of 25 pts)
55.0% (11 of 20 pts)
(analysis group)
20.0% (4 of 20 pts)
(analysis group)
10.7% (3 of 28 pts) 64.3% (18 of 28 pts)preliminary trials were positive, leading investigators torecommend further study examining the efficacy of stem
cell therapy for PAD.6,9,11,12,14,22,26,27,29,31,33-36 The pur-
pose of the current study was to present short-term results
of dual intramuscular and intra-arterial autologous BM-
MNC implantation for the treatment of patients with se-
vere PAD for whom amputation was recommended. To
our knowledge, it is the first report of this type of stem cell
therapy for PAD from investigators in the United States.
The goal of this type of stem cell therapy is to promote
neoangiogenesis, thereby increasing circulation, reducing
symptoms, and facilitating wound healing in patients with
PAD by injecting autologous mononuclear cells obtained
from bone marrow of the iliac crest into various low-
oxygenated ischemic sites of the lower extremity. After
stem cell isolation, no pre-selection or cell sorting was
conducted. Mononuclear cell types including hematopo-
etic cells, angioblasts, and mesenchymal cells, were trans-
planted to allow multiple means of regeneration.15 Similar
to the technique described by Bartsch et al, both intra-
angrene (%) Mean pre-BM-MNC ABI
% (3 of 9 pts) Dorsalis pedis  0.21 (r, 0.00-0.50)
Posterior tibial  0.26 (r, 0.00-0.48)
NA NA
NA 0.66
NA 0.57 (0.00-1.00)
NA 0.75 (r, 0.31-1.16)
NA NA
NA 0.41 (r, 0.20-0.75)
NA NA
NA NA
NA 0.26 (r, 0.12-0.47)
NA NA
NA NA
38.0% 0.40
% (5 of 12 pts) 0.30-0.32 (median)
NA 0.52 (r, 0.00-1.09)
NA NA
NA 0.71 (r, 0.34-1.10)
% (4 of 10 pts) 0.39
NA 0.38 (r, 0.19-0.60)
NA 0.54 (r, 0.00-1.32)
NA NA
% (8 of 25 pts) 0.34
% (10 of 20 pts)
nalysis group)
0.37
(analysis group)
NA 0.52G
33.3
41.7
40.0
32.0
50.0
(aarterial and intramuscular injections were used in the cur-
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in the ischemic area and increase cell invasion.15 The intra-
arterial injection portion of this combined technique en-
sures that the stem cells reach all targeted vessels in an
antegrade manner, allowing ischemic muscle regions that
still are perfused to receive a high concentration of stem
cells.15 The intramuscular injection enables ischemic mus-
culature to receive a high concentration of stem cells
through several local sites, which results in local dispersion
into the surrounding muscle.15 Because most patients with
advanced PAD have multi-level disease, including extensive
pathology of the femoropopliteal tract and pedal arteries,
the exclusive use of intramuscular injections, especially
when limited to the calf, theoretically may not affect these
regions, which may be accessed by intra-arterial injec-
tions.32 Conversely, local intramuscular injections may be
of particular importance for those patients who have super-
ficial femoral artery occlusions that would prevent stem cell
injections intra-arterially from reaching ischemicmuscles.15
No procedure-related complications were reported
during the technique or at the follow-up evaluations. Mean
improvements of 0.13 and 0.09 in ABI were observed after
the BM-MNC implantation for the dorsalis pedis and pos-
terior tibial ankle arteries, respectively. Major amputation
Table VIII. Comparison of outcomes between previously
lower extremity ischemia
Study definition of succ
(follo
Current study, 2009 Success definition (3 mos
1) Improvement of ABI;
2) Absence of rest pain;
3) Ulcer healing, if applic
4) No major amputations
Other studies using intra-arterial and intramuscular BM-MNC im
Van Tongeren et al, J Cardiovasc
Surg 200832
Success definition (1 mos
1) Full wound recovery; a
2) Doubling of walking d
Bartsch et al, Clin Res Cardiol
200715
Primary endpoints (2 mo
1) Maximum walking dist
2) ABI (at rest/after tread
3) Venous occlusion pleth
4) Thigh and lower leg ca
saturation
Other studies including severe PAD
Higashi et al, Circulation 200412 NA (1 mos/6 mos)
Tateishi et al, Lancet 200214 Success definition (1 mos
1) ABI  0.1
2) Transcutaneous oxyge
3) Rest pain
Tateishi et al, Lancet 200214 Success definition (1 mos
1) ABI  0.1
2) Transcutaneous oxyge
3) Rest pain
ABI, Ankle brachial index; BM-MNC, bone marrow mononuclear cell.was avoided in six (66.7%) of the nine patients undergoingBM-MNC implantation through a mean follow-up of 7.8
months. These six patients also showed improvement in
symptom severity three months after the procedure, as
evidenced by alleviation of rest pain and improvements by
at least one level in Rutherford and Fontaine classifications.
In addition, complete wound healing was achieved within
three months in all three patients who had ulcers prior to
BM-MNC implantation and for whom amputation was not
required. This specific BM-MNC implantation technique
was fully successful in three (33.3%) patients, as major
amputation was avoided and other applicable criteria were
met. Five (55.6%) additional patients demonstrated success
in at least one of the four criteria. The three (33.3%)
patients who underwent major amputation all exhibited
Rutherford III and Fontaine IV classifications, which are
the most severe chronic limb ischemia and PAD classifica-
tions. One patient underwent a BKA 4.1 weeks after the
BM-MNC implantation and two patients underwent AKAs
at 5.4 and 11.0 weeks after the procedure. Because this
study population was comprised of limb salvage patients,
any improvement in PAD and postponement of major
amputation should be considered successful. Furthermore,
after BM-MNC implantation, sufficient blood flow was
established so that three of the five patients requiring
lished studies utilizing BM-MNC for the treatment of
primary endpoints
Mean post-BM-MNC ABI
and
Dorsalis pedis  0.34 (r, 0.00-0.74)
Posterior tibial  0.31 (r, 0.00-0.69)
ation
os/12 mos):
r
e.
NA
mos):
test);
graphy; and
y-venous oxygen
0.80/0.80 (2 mos/13 mos)
0.39 (r, 0.22-0.62) at 4 wks
0.35 (r, 0.21-0.59) at 24 wks
os) improvement in:
sure; and
0.47 at 4 wks
os) improvement in:
sure; and
0.46 at 4 wkspub
ess or
w-up)
)
able;
plant
/6 m
nd/o
istanc
s/13
ance;
mill
ysmo
pillar
/6 m
n pres
/6 m
n prespost-implantation amputations received more limited am-
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not participated in the study.
Comparison of outcomes between lower extremity
stem cell therapy studies is difficult, as several different
injection techniques were used, indications for stem cell
therapy varied, and differences in patient populations exist
(Tables VI and VII). Several single-injection site studies
involving intra-arterial injections5,6,26,33 and many stud-
ies utilizing intramuscular injections9,11,12,14,21,22,27,29-36
have shown promising results. In addition, the two other
groups using combined intra-arterial and intramuscular
injections also reported successful outcomes.3,15,32 Bartsch
et al also had a novel addition to their technique involving
ischemic preconditioning by incorporating exercise prior to
injection and using a blood pressure cuff as a tourniquet to
compress the thigh for a few minutes after the intra-arterial
injection, thereby creating a stop flow in the leg to extend
contact between the stem cells and ischemic tissue.3,15
Promising results also have been reported using a com-
bined intramuscular and intermetatarsal injection tech-
nique.28
The majority of lower extremity stem cell therapy stud-
ies include patients with mild forms of PAD (ABI 
0.70)5,6,26,32 or solely included patients with thromboan-
Table VIII. Continued.
Absence of rest pain (%)
Complete ulcer
healing (%)
100.0% (5 of 5 pts) 62.5% (5 of 8 pts)
NA NA
NA NA
100.0% (Pain-free walking) NA
48.0% (12 of 25 pts) 50.0% (3 of 6 pts)
50.0% (10 of 20 pts) 75.0% (3 of 4 pts)giitis obliterans (TAO, Buerger’s disease) or atherosclerosisobliterans (ASO).9,11,27,28,30,31,34-36 Only two previously
published studies (both using intramuscular injection tech-
niques) have included patients with severe PAD (mean ABI
 0.40).12,14
Comparing these two studies with the current study,
the study population sizes of the three studies ranged from
seven to 25 patients (Table VI).12,14 The current study was
comprised of an approximately equal number of females
and males, whereas the other two studies involved a dispro-
portionately higher percentage of males (Table VI).12,14
All three study populations involved patients with consid-
erable co-morbidities; however, the Higashi et al study
excluded patients with diabetes (Table VII).12,14 The study
by Tateishi et al had considerably fewer patients with non-
healing ulcers than the other two studies (Table VII).12,14
The mean pre-treatment ABI measurements in each of the
three studies corresponded to severe PAD (ABI  0.40)
(Table VII).12,14 Improvement in ABI measurements after
BM-MNC implantation were reported for all three studies;
however, the mean post-procedure ABI measurements re-
mained in the severe PAD range in the Higashi et al and
current studies, but corresponded to moderate PAD
(ABI  0.70) in the Tateishi et al study (Table VIII).12,14
All patients in the Higashi et al study had pain-free ambu-
Major
amputation (%)
Success rate per study
definition or endpoint results
33.3% (3 of 9 pts) 33.3% (3 of 9 pts)
16.7% (2 of 12 pts) 66.7% (8 of 12 pts)
NA (2 mos/13 mos, all stat sign)
1) Mean  500 m/542 m;
2) Rest mean  0.80/0.80,
Stress mean  0.76/0.75;
3) Rest mean  2.5/2.6,
Reactive hyperemia
Mean  7.2/6.8;
4) Thigh mean  66/67,
Lower leg mean  63/66
0.0% NA
0.00% 1) 68.0% (17 of 25 pts)
2) 100% (25 of 25 pts)
3) 48.0% (12 of 25 pts)
0.00% 1) 65.0% (13 of 20 pts)
2) 100% (20 of 20 pts)
3) 50.0% (10 of 20 pts)lation after the procedure, whereas no patients in the cur-
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Tateishi et al study did not have rest pain (Table VIII).12,14
The majority of ulcers healed in both the current study and
that by Tateishi et al (Table VIII).12,14 Finally, major
amputations were performed in three patients in the cur-
rent study, but were not required in the other two stud-
ies.12,14
The three studies that examined the dual intra-arterial
and intramuscular injection technique, including the cur-
rent one, utilized the procedure in populations of less than
15 patients (Table VI).15,32 The other two studies had
male:female gender ratios of approximately 3:1, compared
with the nearly equivalent gender distribution in the cur-
rent study (Table VI).15,32 The current study involved
patients with considerably more co-morbidities than the
previous dual injection studies and, unlike the other stud-
ies, included patients with non-healing ulcers (Table
VII).15,32 The Van Tongeren et al study included patients
with mild PAD (ABI  0.70).32 The mean pre-treatment
dorsalis pedis and posterior tibial ABI measurements of
0.21 and 0.26, respectively, in the current study corre-
sponded to severe PAD (ABI  0.40), compared with the
mean ABI of 0.66 in the Bartsch et al study that corre-
sponded tomoderate ABI (ABI 0.7) (Table VII).15 Both
studies demonstrated improvement in ABI after the proce-
dure, with the dorsalis pedis and posterior tibial ABI mea-
surements of 0.34 and 0.31, respectively, in the current
study remaining in the severe PAD range, compared with
the mean ABI of 0.80 in the Bartsch et al study that
corresponded tomild PAD (Table VIII).15,32 Two (16.7%)
patients in the Van Tongeren et al and three (33.3%)
patients in the current study required major amputations
after the procedure (Table VIII).15,32
Finally, in an effort to compare results between all of
the published lower extremity stem cell studies, the per-
centage of patients experiencing an increase of more than
0.1 in ABI measurements after stem cell implantation is
Table IX. A comparison of study population percentages
stem cell therapy
Intra-arterial and intramuscular BM-MNC implantation
Current Study, 2009
Intra-arterial BM-MNC implantation
Cobellis et al, Bone Marrow Transplant 20085
Gu et al, Chin Med J 200833
Napoli et al, Eur J Cardio Prev Rehab 20086
Intramuscular BM-MNC implantation
Gu et al, Chin Med J 200833
Motukuru et al, J Vasc Surg 200831
Hernandez et al, Atherosclerosis 200729
Kajiguchi et al, Circ J 20079
Miyamoto et al, Circulation 200630
Esato et al, Cell Transplant 200211
Tateishi et al, Lancet 200214
ABI, Ankle brachial index; BM-MNC, bone marrow mononuclear cell.presented in Table IX. Using this widely accepted defini-tion of vascular function improvement, which was first
proposed by Rutherford et al and also was used in the
seminal stem cell study by Tateishi et al, five (45.5%) of 11
studies, including the current study, demonstrated im-
provement in the majority of patients.6,14,24,29,31
The minimally invasive nature of the injection proce-
dure itself and the use of autologous cells make stem cell
therapy an attractive option for managing a wide range of
ischemic conditions, as demonstrated by previous studies
and confirmed by the current study. Besides lending further
support to the growing list of studies recommending stem
cell therapy for the management of PAD, the successful
results of the current study also add several new findings.
First, this study is only the third report involving dual
intramuscular and intra-arterial injection and the first uti-
lizing the dual technique in more complex cases, including
in the presence of non-healing ulcers. Because all three
studies documented improvement, attempting to promote
neoangiogenesis through multiple physiological pathways
appears beneficial and warrants further study. Second, un-
like previous studies, most of which used stem cell therapy
to treat earlier stages of PAD, the current study utilized
BM-MNC implantation as a means of limb salvage therapy.
Additional alternatives are desperately needed for patients
with end-stage PAD who currently have few management
options available other than amputation. Overall survival
after BKA and AKA has been reported to be 70% and 35%
at one and five years, respectively.37 Therefore, avoiding or
even postponing amputation has a significant impact on
patient quality of life and survival. Third, the study popu-
lation in this study is more heterogeneous than those in
previous studies and, therefore, may better represent the
general PAD patient population as a whole. In addition,
since BM-MNC implantation was utilized in patients with
complex medical conditions, including severe PAD, the
presence of significant co-morbidities, and open ulcers in all
but one case, these “worse case” results suggest that this
ABI improvement greater than 0.1 after lower extremity
M-MNC implantation technique
% of cases with ABI
improvement  0.1
Intra-arterial & Intramuscular 55.6% (5 of 9)
Intra-arterial 40.0% (4 of 10)
Intra-arterial 41.2% (7 of 17)
Intra-arterial 55.6% (10 of 18)
Intramuscular 44.4% (8 of 18)
Intramuscular 91.7% (33 of 36)
Intramuscular 64% NA
Intramuscular 42.9% (3 of 7)
Intramuscular 28.6% (2 of 7)
Intramuscular 12.5% (1 of 8)
Intramuscular 66.7% (30 of 45)with
Bstem cell therapy procedure may be beneficial not only to
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of the disease. Many studies also either entirely excluded
patients with diabetes or those with poorly controlled or
uncontrolled diabetes, whereas 77.8% of patients in the
current study had diabetes.6,12,14,22,31,34,36 Again, the re-
sults of studies with strict inclusion criteria or those limited
to conditions such as ASO or TAO, which affect very
specific patient populations, may not accurately depict the
results that may be expected in the typical PAD patient with
diabetes.
Study limitations include the small population size, lack
of a control group, and absence of long-term follow-up. A
prospective control group was not feasible, as the senior
investigator (R.W.F.) did not wish to withhold this prom-
ising treatment from patients who were at end stages of the
disease and for whom amputation was the only alternative.
Another challenge for all stem cell studies is demonstrating
proof of neoangiogenesis, as visual demonstration is diffi-
cult due to inherent variability in technique and diagnostic
imaging protocols. In light of this difficulty and because
this particular study population involved patients with end-
stage PAD who had significant co-morbidities, the senior
author chose not to place patients at unnecessary risk by
including follow-up angiography as part of the study pro-
tocol. The patients who did not undergomajor amputation
after BM-MNC implantation will continue to be followed
up to establish a long-term prognosis of the technique and
to assist in shaping surgeon and patient expectations of the
procedure.
Because the research involving BM-MNC implantation
is in its infancy, many questions remain. Histological anal-
ysis of amputated specimens would assist in determining
the cause of tissue loss and locating possible areas of robust
neovascular response to verify neoangiogenesis. Endothe-
lial surface marker testing or tissue mitogen assays also
would assist in understanding the physiological response to
BM-MNC implantation. Additional study involving the
use of BM-MNC implantation as a limb salvage technique
is crucial so that patients in end stages of PAD may be
provided with alternatives to avoid or postpone amputa-
tion. General multi-center prospective stem cell therapy
studies for the management of PAD would be beneficial so
that its efficacy could be examined using this standardized
technique and in a larger patient population. The ideal
number of intramuscular injection sites also has not been
elucidated, with techniques ranging from one to 90 sites
reported in the literature.9,11,12,14,15,21,22,27-36 Finally, as
recommended for other PAD management procedures,
standards for evaluation and reporting the results of stem
cell therapies are critical to compare results between stud-
ies.
In conclusion, eight (88.9%) of nine patients showed
some level of clinical improvement after BM-MNC implan-
tation, suggesting that the therapeutic goal of improving
limb perfusion was achieved. In three cases, more limited
amputations were performed than would have been re-
quired had the patients not undergone BM-MNC implan-
tation. Three patients with the most severe classifications ofchronic ischemia and PAD possible required major ampu-
tations, but amputation was postponed one to three
months. All amputation sites healed following surgery.
Major amputation was avoided in six (66.7%) patients, who
have not required amputation at a mean follow-up of 7.8
months. Complete wound healing was achieved within
three months in all patients who had ulcers prior to BM-
MNC implantation and for whom amputation was not
required. These short-term results indicate the use of BM-
MNC implantation as a means of limb salvage therapy for
patients with severe PAD shows promise in postponing or
avoiding amputation in a patient population currently pre-
sented with few alternatives to amputation. Furthermore,
in light of these encouraging results achieved in “worst-
case” scenarios and based on results in the literature, the
authors plan to perform the procedure earlier in the
treatment plan of patients with severe ischemia or non-
healing ulcers. Future study also is warranted to deter-
mine if patients with moderate PAD may also benefit
from this procedure.
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